Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

(2016) Keith M. Kerr et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society

(2016) Lynette M. Sholl et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

(2016) Pedro N Aguiar et al.   Immunotherapy

PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases

(2016) Emanuela Veras et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

(2016) Andreas H Scheel et al.   MODERN PATHOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

Biomarkers for personalized oncology: recent advances and future challenges

(2015) Madhu Kalia   METABOLISM-CLINICAL AND EXPERIMENTAL

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

(2014) K. M. Kerr et al.   ANNALS OF ONCOLOGY

Immune Checkpoint Blockade

(2014) Jarushka Naidoo et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells

(2014) Hatem Soliman et al.   PLoS One

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Co-development of a companion diagnostic for targeted cancer therapy

(2012) Suzanne Cheng et al.   New Biotechnology